Risk assessment for biochemical recurrence improved with addition of PSMA PET N1\/M1 status to presurgical Cancer of the Prostate Risk Assessment score<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, July 31, 2023 (HealthDay News) — Presurgical 68<\/sup>Ga-prostate-specific membrane antigen positron emission tomography (PSMA-PET) improves prediction of biochemical recurrence-free survival (BCR-FS) for patients with intermediate- to high-risk prostate cancer, according to a study published online July 21 in European Urology<\/em>.<\/p>\n Lo \u00afc Dja \u00afleb, M.D., Ph.D., from the David Geffen School of Medicine at the University of California Los Angeles, and colleagues conducted a follow-up study of a surgical cohort assessed in a prospective phase 3 imaging trial involving 277 patients with intermediate- to high-risk prostate cancer treated with radical prostatectomy and pelvic lymph node dissection. The added prognostic value of presurgical PSMA-PET for BCR-FS compared to the presurgical Cancer of the Prostate Risk Assessment (CAPRA) and postsurgical CAPRA-Surgery (CAPRA-S) scores was assessed.<\/p>\n Patients were followed for a median of 32.4 months after surgery; clinical follow-up was available for 240 patients. The researchers found that 91 of 240 BCR events were observed (38 percent). In 17 percent of patients, PSMA-PET extraprostatic disease (N1\/M1) was found. Significant univariate predictors of BCR included PSMA-PET prostate uptake, PSMA-PET N1\/M1, and CAPRA and CAPRA-S scores. The risk assessment for BCR was significantly improved with the addition of PSMA-PET N1\/M1 status to the presurgical CAPRA score compared with the presurgical CAPRA score alone (C-statistic, 0.70 versus 0.63). There was no significant difference observed for the C-index of the postsurgical model utilizing the postsurgical CAPRA-S score alone from the presurgical model combining the presurgical CAPRA score and PSMA-PET N1\/M1 status.<\/p>\n “In patients with prostate cancer considered for surgery, PSMA PET can provide information on the risk of recurrence after surgery, before the surgery even happens,” Dja \u00afleb said in a statement.<\/p>\n Several authors disclosed ties to the biopharmaceutical industry.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n